4//SEC Filing
MPM BIOVENTURES 2018, L.P. 4
Accession 0001209191-21-060724
CIK 0001808865other
Filed
Oct 17, 8:00 PM ET
Accepted
Oct 18, 4:35 PM ET
Size
15.8 KB
Accession
0001209191-21-060724
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2021-10-18$27.14/sh−6,167$167,372→ 3,134,991 total(indirect: See Footnote) - Sale
Common Stock
2021-10-15$27.53/sh−8,893$244,824→ 3,143,197 total(indirect: See Footnote) - Sale
Common Stock
2021-10-15$28.01/sh−2,039$57,112→ 3,141,158 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2021-10-15$27.53/sh−8,893$244,824→ 3,143,197 total(indirect: See Footnote) - Sale
Common Stock
2021-10-18$27.14/sh−6,167$167,372→ 3,134,991 total(indirect: See Footnote) - Sale
Common Stock
2021-10-15$28.01/sh−2,039$57,112→ 3,141,158 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2021-10-15$28.01/sh−2,039$57,112→ 3,141,158 total(indirect: See Footnote) - Sale
Common Stock
2021-10-15$27.53/sh−8,893$244,824→ 3,143,197 total(indirect: See Footnote) - Sale
Common Stock
2021-10-18$27.14/sh−6,167$167,372→ 3,134,991 total(indirect: See Footnote)
Footnotes (10)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
- [F10]The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B) and 22,078 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- [F2]The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. ("BV 2014"), 182 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,347 by MPM BioVentures 2018, L.P. ("BV 2018") and 66 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 22,138 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- [F5]The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018 and 15 by AM BV2018.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B) and 22,123 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- [F8]The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by BV 2018 and 45 by AM BV2018.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
iTeos Therapeutics, Inc.
CIK 0001808865
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001729505
Filing Metadata
- Form type
- 4
- Filed
- Oct 17, 8:00 PM ET
- Accepted
- Oct 18, 4:35 PM ET
- Size
- 15.8 KB